Acknowledgments
Participants of Severe Asthma & COPD Network South West Netherlands, besides authors of this research letter:
Esther Vis, MD – Department of Pulmonary medicine, Admiraal de Ruiter ziekenhuis
Chantal Kroese, MD – Department of Pulmonary medicine, Ikazia, Rotterdam, the Netherlands
Stephanie van Loon-Kooij, MD – Department of Pulmonary medicine, Reinier de Graaf ziekenhuis, Delft, the Netherlands
Jeroen van Exsel, MD – Department of Pulmonary medicine, HAGA, Den Haag, the Netherlands
Dennis van Leeuwen, MD – Department of Pulmonary medicine, Spijkenisse Medisch centrum, Spijkenisse, the Netherlands
Jasmijn van Kampen, MD – Department of Pulmonary medicine, MC Haaglanden, Den Haag, the Netherlands
Maurice Jans, MD – Department of Pulmonary medicine, Rivas Beatrixziekenhuis, Gorinchem, the Netherlands
Jelmer Vahl, MD – Department of Pulmonary medicine, Ijsselland ziekenhuis, Capelle aan den IJssel
Remco Djamin, MD – Department of Pulmonary medicine, Amphia ziekenhuis, Breda, the Netherlands
Jacobine Herbrink, MD – Department of Pulmonary medicine, Het van Weel-Bethesda ziekenhuis, Dirksland, the Netherlands
Wouter Blox, MD – Department of Pulmonary medicine, Albert Schweitzer ziekenhuis, Dordrecht, the Netherlands
Jeroen Retera, MD – Department of Pulmonary medicine, Elisabeth-TweeSteden ziekenhuis, Tilburg, the Netherlands
Yordi van Dooren, MD – Department of Pulmonary medicine, Groene Hart ziekenhuis, Gouda, the Netherlands
Disclosure
Dr Gert-Jan Braunstahl reports grants and/or personal fees from GSK, Sanofi, AstraZeneca, ALKAbello, outside the submitted work. Dr Johannes In ‘t Veen reports Unrestricted grant to institution from Teva, Astra Zeneca, Chiesi; Speaker Bureau for Sanofi, Chiesi, GSK, Astra Zeneca, Health Investment, StichtingRoLeX. The authors report no other conflicts of interest in this work.